# Are plasma citrulline levels a reliable marker of residual intestinal length and enterocyte mass?

I. Pinar<sup>1</sup>, M.K. Hvistendahl<sup>1</sup>, J.H.M. Andersen<sup>1</sup>, S. Lund<sup>1</sup>, K.K. Rasmussen<sup>1</sup>, C.F. Brandt<sup>1</sup>, J.M.W. van den Ouweland<sup>2</sup>, P.B. Jeppesen<sup>1</sup>.

- <sup>1</sup> Department of Intestinal Failure and Liver Diseases, Rigshospitalet, Copenhagen, Denmark.
- <sup>2</sup> Department of Clinical Chemistry, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.

## PLASMA CITRULLINE LEVELS IN PATIENTS WITH SHORT BOWEL SYNDROME

P073-W



### Background

In recent years, the amino acid citrulline has gained scientific attention due to its unique metabolism, prompting suggestions that plasma citrulline may be a reliable marker of residual intestinal function and enterocyte mass<sup>1</sup>. Circulating citrulline are dependent on mainly de novo synthesis from the small bowel mucosal enterocytes, and no other cells are believed to produce significant amounts of citrulline. The aim of this study was to measure citrulline concentration in healthy controls and in four anatomical distinct groups of patients with short bowel syndrome (SBS).




### 31 patients included.


Blood samples were obtained after an overnight oral fast. For patients with intestinal failure, usual parenteral nutritional prescription was adjusted the night before study day, and nutrition was replaced with an isovolumic saline infusion.

Plasma citrulline levels were measured by liquid chromatography-tandem mass spectrometry (reference value in healthy control subjects: 30.5 µmol/L ± 8.8).


Kruskal-Wallis test used for comparison of anatomical groups. Spearman correlation coefficients were used to compare small bowel lengths to citrulline levels.




**GROUP 1A** End jejunostomy



**GROUP 1B** End ileostomy Preserved jejunum




**GROUP 2** Jejuno-colonicanatomosis



**GROUP 3** Jejuno-ilealanastomosis and preserved colon



### Results



Plasma concentrations of Citrulline (µmol/l) in patients with short bowel syndrome and healthy controls

		Group					
		1A N=8	1B N=8	2 N=7	3 N=8	Healthy controls N=8	
Gender	(Female %)	4 (50 %)	7 (88 %)	3 (43 %)	4 (50 %)	4 (50 %)	
Age		56.8 (32.1-72.9)	53.7 (27.3-78.0)	56.1 (43.6-74.2)	63.4 (34.9-75.0)	40.4 (32.0-74.9)	0.11
ВМІ	(kg/m²)	23.1 (17.2-27.2)	24.5 (20.5-29.0)	22.8 (21.2-28.6)	22.1 (21.6-32.3)	23.2 (18.3-25.9)	0.34
II / IF		3 / 5	7 / 1	4/3	8 / 0	-	
Small bowel leng	gth (cm)	108 (50-150)	333 (275-350)	110 (100-130)	115 (60-230)	-	
Colon length	(%)	-	-	71 (64-86)	100 (100-100)	-	
Causes of SBS  IBD / SC / thrombosis / other		7/0/0/1	7/1/0/0	6/1/0/0	1/2/5/0	-	
Years from last surgery		9.6 (6.8-20.0)	14.3 (5.2-31.1)	8.8 (0.5-17.6)	9.4 (1.3-31.8)	-	
Citrulline	(µmol/L)	24.5 (4.7 – 36.9)	32.7 (21.0 - 43.4)	24.6 (20.7 - 32.5)	27.3 (16.1 - 48.4)	27.6 (19.9 - 34.2)	0.09
Creatinine	(µmol/L)	78.0 (67.0 - 112.0)	69.5 (55.0 - 92.0)	88.0 (63.0 - 156.0)	78.5 (49.0 - 126.0)	75.5 (58.0 - 93.0)	0.38
eGFR	(ml/min)	83.5 (56.0 - 90.0)	88.5 (52.0 - 90.0)	81.0 (42.0 - 90.0)	79.5 (48.0 - 90.0)	90.0 (79.0 - 90.0)	0.51

Data presented as median (min-max). II: Intestinal insufficiency. IF: Intestinal failure. Colon length measured in cummings percentage IBD: Inflammatory bowel disease. SC: Surgical complication



### **Summary/ Highlights**

No differences in plasma citrulline levels were evident across the four distinct anatomical groups of SBS patients, with all groups demonstrating citrulline concentrations comparable to healthy controls. Notably, large individual variations in citrulline levels were observed within each anatomical group. In line with previously published papers 1, it was observed that plasma citrulline levels correlate with remaining length of small bowel across the anatomical groups.

However, subgroup analyses revealed a statistically significant correlation only among patients with the shortest bowel length (Group 1A). This implies that citrulline may be a complex marker to interpret in SBS patients with ileostomies and colon-incontinuity.





505.

